Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, United States.
Front Immunol. 2024 Feb 6;15:1336476. doi: 10.3389/fimmu.2024.1336476. eCollection 2024.
Glioblastoma (GBM) accounts for approximately half of all malignant brain tumors, and it remains lethal with a five-year survival of less than 10%. Despite the immense advancements in the field, it has managed to evade even the most promising therapeutics: immunotherapies. The main reason is the highly spatiotemporally heterogeneous and immunosuppressive GBM tumor microenvironment (TME). Accounting for this complex interplay of TME-driven immunosuppression is key to developing effective therapeutics. This review will explore the immunomodulatory role of the extracellular matrix (ECM) by establishing its contribution to the TME as a key mediator of immune responses in GBM. This relationship will help us elucidate therapeutic targets that can be leveraged to develop and deliver more effective immunotherapies.
胶质母细胞瘤（GBM）约占所有恶性脑肿瘤的一半，其五年生存率仍低于 10%，属于致命疾病。尽管该领域取得了巨大进展，但它甚至能逃避最有前途的疗法：免疫疗法。主要原因是胶质母细胞瘤肿瘤微环境（TME）具有高度时空异质性和免疫抑制性。了解 TME 驱动的免疫抑制的这种复杂相互作用对于开发有效的治疗方法至关重要。本综述将通过确定细胞外基质（ECM）在 TME 中的免疫调节作用，探讨 ECM 对 TME 的贡献，因为 ECM 是 GBM 中免疫反应的关键介质。这种关系将有助于我们阐明治疗靶点，以开发和提供更有效的免疫疗法。
